Results 21 to 30 of about 148,576 (255)
American Journal of Neuroradiology, 2011 Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with ...
J, Comin, D, Kallmes
openaire +2 more sources
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) [PDF]
, 2018 The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke.
International Clopidogrel Pharmacogenomics Consortium
core +4 more sources
Platelets, 2023 Clopidogrel combined with aspirin is widely used in coronary artery disease (CAD) patients, while some patients exhibit high platelet activity when receiving the combined treatment. Current environmental and genetic factors could only explain part of the
Xiaolei Hu +9 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2023 BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo +4 more
doaj +1 more source
Pakistan Journal of Pharmaceutical Sciences, 2023 To evaluate the efficacy of nitroglycerin plus clopidogrel for acute myocardial infarction and the effect on the cardiac function indices. From April 2019 to April 2020, 90 patients with acute myocardial infarction enrolled in our hospital were recruited
Cui Xie, Miao He, Yang Xiang
doaj +1 more source
Drug interactions and hepatotoxicity of clopidogrel [PDF]
, 2010 Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core +1 more source
Journal of Pharmaceutical Health Care and Sciences, 2020 Background Repaglinide is widely prescribed to reduce postprandial hyperglycemia and elevated glycated hemoglobin (HbA1c) levels associated with type 2 diabetes, and clopidogrel is a thienopyridine antiplatelet agent and widely used in cardiovascular and
Yuuki Akagi +9 more
doaj +1 more source
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). [PDF]
, 2011 AIMS: Adherence to evidence-based treatments and its consequences after acute myocardial infarction (MI) are poorly defined. We examined the extent to which clopidogrel treatment initiated in hospital is continued in primary care; the factors predictive ...
Van Staa, Tjeerd; id_orcid +25 more
core +1 more source
Drug resistance with monitored adherence [PDF]
, 2013 Drug resistance can be defined as the failure of a drug to exert its expected effect on pharmacological biomarkers and is caused by pharmacogenetic, cellular or clinical factors.
Walter, Philipp Niklaus
core +1 more source
Atorvastatin and Clopidogrel [PDF]
Circulation, 2003 To the Editor: I would like to comment on the recent editorial by Serebruany et al1 in which the study results by Lau et al2 are discussed. It is argued that these results, which are suggestive of a clinically relevant interaction between clopidogrel and atorvastatin, are in conflict with those published previously by Serebruany et al.3 According to ...
openaire +2 more sources